Skip to content
Screener

Aurinia Pharmaceuticals AUPH Visp, Switzerland — Total

Similar metrics at other companies

Snowflake logo
SNOWOther — Total
$128.88M+17.9%
AECOM logo
ACMAmericas — Total
$3.78B+14.0%
Beta Technologies logo
BETAInternational — Total
$559K
The Cooper Companies, Inc. logo
COOEurope — Total
$445.7M+7.9%
Veritone, Inc. logo
VERIDomestic — Total
-$22.76M-24.4%
Veritone, Inc. logo
VERIForeign — Total
-$5.23M+22.6%

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+35.7%
Enterprise value$1.98B+25.5%
P/E6.6×-18.6×
P/S6.7×+0.8×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062

The Monoplant arrangement was determined to be an embedded lease and is accounted for as a finance lease under ASC 842. The lease term is based on the non-cancellable period for which a lessee has the right to use an underlying asset (the “Monoplant Lease”). The Company determined that the Monoplant Lease commencement occurred at the point when the FDA manufacturing validation process began, which occurred on June 26, 2023. At lease inception, the Company recorded a finance right-of-use (“ROU”) lease asset and a corresponding lease liability. As of June 30, 2026, the Monoplant Lease finance ROU lease asset and corresponding lease liability balance were $65.2 million and $60.4 million, respectively.

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's visp, switzerland — total?
Aurinia Pharmaceuticals (AUPH) reported visp, switzerland — total of $60.4M in Q2 2026.
How has Aurinia Pharmaceuticals's visp, switzerland — total changed year-over-year?
Aurinia Pharmaceuticals's visp, switzerland — total decreased by 19.9% year-over-year, from $75.4M to $60.4M.
What does visp, switzerland — total mean?
Represents the aggregate financial value or operational output attributed to the Visp, Switzerland geographic segment. This metric serves as a high-level indicator of the segment's overall contribution to the company's financial position or operational footprint. It is used to evaluate the relative importance and performance of this specific region within the broader corporate structure.

Ask your AI about Aurinia Pharmaceuticals's visp, switzerland — total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude